Review
Open access
Sep 2026
Integrating new and “old” cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma
Clinical management of R/R LBCL becomes highly complex in peculiar settings, especially in case of multiple relapses even after CAR T-cell therapy, as described in the clinical case of secondary central nervous system disease relapse.
Enrico Amaducci, M. Clerico, Davide Camoirano et al.
· Frontiers in Oncology · 0 citations